MBX rises on obesity drug data showing monthly dosing potential

ReutersMay 11, 2026 3:42 PM

View all comments（0）



Shares of MBX Biosciences MBX.O climb 6% to $43.42

The biotech firm says preliminary blinded data for obesity drug MBX 4291 showed about 7% mean weight loss at eight weeks by targeting appetite and metabolism-related hormones

Adds that drug designed for once-monthly dosing with gradual release profile supporting steady exposure

Only one mild gastrointestinal side effect reported; no serious adverse events - MBX

Says 12-week data due Q4 2026, key for confirming durability

Names new next-gen obesity candidate MBX 5765, targeting multiple pathways for improved efficacy

The minimal gastrointestinal side effects seen so far are an encouraging sign that the prodrug platform could support a differentiated tolerability profile - TD Cowen analysts

MBX says it achieved proof of concept for imapextide in low blood sugar condition after weight-loss surgery

Including session's move, stock up ~38% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Anthropic in Talks for Massive $30 Billion Funding, Valuation May Join Trillion-Dollar Ranks

TradingKey - On May 12, Eastern Time, Bloomberg reported that AI startup Anthropic is in preliminary discussions with investors to raise at least $30 billion in new capital at a pre-money valuation exceeding $900 billion. If the deal is finalized, it would mark the company's largest funding round to

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools